Pioneering partnership supports early-stage innovation against antimicrobial resistance to save lives

Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced its first funding call with up to £10 million available to support innovators developing new antimicrobials.

MSD’s Welireg secures FDA approval for renal cell carcinoma – Pharmaceutical Technology

Share this article The FDA based its decision for the second approval of the drug on results from MSD’s LITESPARK-005 trial (NCT04195750). Image credit: Shutterstock/Magic

December 15, 2023

Cell therapy startup ArsenalBio raises $325M as it runs early solid tumor trials

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 5, 2024

Adaptive Biotechnologies trims handful of jobs as strategic review nears completion

Adaptive Biotechnologies, a Seattle-based diagnostics maker and drug discovery company, told Endpoints News it recently eliminated 6.7% of its workforce as part of its strategic

February 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.